4-anilino-6-chloroquinoline-3-carboxylic acid | 24337-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-anilino-6-chloroquinoline-3-carboxylic acid
• 英文别名: 4-Anilino-6-chlor-chinolin-3-carbonsaeure；6-Chloro-4-(phenylamino)-3-quinolinecarboxylic acid
• CAS: 24337-70-0
• 化学式: C₁₆H₁₁ClN₂O₂
• 分子量: 298.729
• InChiKey: XLJLTKXDZSNYBX-UHFFFAOYSA-N

物化性质

• 熔点：
  260-262 °C
• 沸点：
  460.8±45.0 °C(Predicted)
• 密度：
  1.441±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-anilino-6-chloroquinoline-3-carboxylic acid 在 potassium phosphate 、 XPhos Pd G2 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 N-cyclopropyl-6-(4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1-carbonyl)phenyl)-4-(phenylamino)quinoline-3-carboxamide
  参考文献：
  名称：

  Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability

  摘要：

  Tumor cells must rewire nucleotide synthesis to satisfy the demands of unbridled proliferation. Meanwhile, they exhibit augmented reactive oxygen species (ROS) production which paradoxically damages DNA and free deoxy-ribonucleoside triphosphates (dNTPs). How these metabolic processes are integrated to fuel tumorigenesis remains to be investigated. MYC family oncoproteins coordinate nucleotide synthesis and ROS generation to drive the development of numerous cancers. We herein perform a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based functional screen targeting metabolic genes and identified nudix hydrolase 1 (NUDT1) as a MYC-driven dependency. Mechanistically, MYC orchestrates the balance of two metabolic pathways that act in parallel, the NADPH oxidase 4 (NOX4)-ROS pathway and the Polo like kinase 1 (PLK1)-NUDT1 nucleotide-sanitizing pathway. We describe LC-1-40 as a potent, on-target degrader that depletes NUDT1 in vivo. Administration of LC-1-40 elicits excessive nucleotide oxidation, cytotoxicity and therapeutic responses in patient-derived xenografts. Thus, pharmacological targeting of NUDT1 represents an actionable MYC-driven metabolic liability.

  DOI：

  10.1038/s41467-024-46572-6
• 作为产物：
  描述：

  苯胺 在 lithium hydroxide monohydrate 、 溶剂黄146 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 水 为溶剂， 反应 9.0h， 生成 4-anilino-6-chloroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability

  摘要：

  Tumor cells must rewire nucleotide synthesis to satisfy the demands of unbridled proliferation. Meanwhile, they exhibit augmented reactive oxygen species (ROS) production which paradoxically damages DNA and free deoxy-ribonucleoside triphosphates (dNTPs). How these metabolic processes are integrated to fuel tumorigenesis remains to be investigated. MYC family oncoproteins coordinate nucleotide synthesis and ROS generation to drive the development of numerous cancers. We herein perform a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based functional screen targeting metabolic genes and identified nudix hydrolase 1 (NUDT1) as a MYC-driven dependency. Mechanistically, MYC orchestrates the balance of two metabolic pathways that act in parallel, the NADPH oxidase 4 (NOX4)-ROS pathway and the Polo like kinase 1 (PLK1)-NUDT1 nucleotide-sanitizing pathway. We describe LC-1-40 as a potent, on-target degrader that depletes NUDT1 in vivo. Administration of LC-1-40 elicits excessive nucleotide oxidation, cytotoxicity and therapeutic responses in patient-derived xenografts. Thus, pharmacological targeting of NUDT1 represents an actionable MYC-driven metabolic liability.

  DOI：

  10.1038/s41467-024-46572-6

文献信息

• [EN] COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1<br/>[FR] COMPOSÉS POUR LA DÉGRADATION DE BRD9 OU MTH1
  申请人：C4 THERAPEUTICS INC

  公开号：WO2020051235A1

  公开（公告）日：2020-03-12

  Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.

  提供了通过泛素蛋白酶体途径降解BRD9或MTH1的化合物，用于治疗需要的受体。提供的化合物具有与BRD9或MTH1的靶向配体相连的E3泛素连接酶靶向基团（Degron）。
• 319. Attempts to find new antimalarials. Part XXX. The synthesis of derivatives of quinolino(4′ : 3′-2 : 3)quinoline
  作者：William O. Kermack、Nora E. Storey

  DOI：10.1039/jr9510001389

  日期：——
• COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
  申请人：C4 Therapeutics, Inc.

  公开号：EP3846800A1

  公开（公告）日：2021-07-14